United States v. Philip Weinstein "Dr. Philip Adamelli", Wilhelmina Harich Weinstein, Solomon Richman, A/K/A "Sol" A/K/A "Silver Fox", Robert "Bobby" Falvo, United States of America v. Stanley Kowitt

762 F.2d 1522, 18 Fed. R. Serv. 757, 1985 U.S. App. LEXIS 30627
CourtCourt of Appeals for the Eleventh Circuit
DecidedJune 12, 1985
Docket83-5260
StatusPublished

This text of 762 F.2d 1522 (United States v. Philip Weinstein "Dr. Philip Adamelli", Wilhelmina Harich Weinstein, Solomon Richman, A/K/A "Sol" A/K/A "Silver Fox", Robert "Bobby" Falvo, United States of America v. Stanley Kowitt) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eleventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Philip Weinstein "Dr. Philip Adamelli", Wilhelmina Harich Weinstein, Solomon Richman, A/K/A "Sol" A/K/A "Silver Fox", Robert "Bobby" Falvo, United States of America v. Stanley Kowitt, 762 F.2d 1522, 18 Fed. R. Serv. 757, 1985 U.S. App. LEXIS 30627 (11th Cir. 1985).

Opinion

762 F.2d 1522

18 Fed. R. Evid. Serv. 757

UNITED STATES of America, Plaintiff-Appellee,
v.
Philip WEINSTEIN "Dr. Philip Adamelli", Wilhelmina Harich
Weinstein, Solomon Richman, a/k/a "Sol" a/k/a
"Silver Fox", Robert "Bobby" Falvo,
Defendants-Appellants.
UNITED STATES of America, Plaintiff-Appellant,
v.
Stanley KOWITT, Defendant-Appellant.

Nos. 83-5260, 83-5570.

United States Court of Appeals,
Eleventh Circuit.

June 12, 1985.

Philip Weinstein and Wilhelmina Harich Weinstein, pro se.

David R. Mackenzie P.A., Lauderhill, Fla., Harvey M. Stone, New York City, for Falvo.

Drew Neville, B.J. Rothbaum, Jr., Oklahoma City, Okl., Richard H. Dolan, New York City, for Richman.

Fine, Jacobson, Block, Klein, Colan & Simon, P.A., Irwin J. Block, Theodore Klein, Miami, Fla., for Kowitt.

Gloria C. Phares, Washington, D.C., for U.S.

Appeals from the United States District Court for the Southern District of Florida.

Before HILL, FAY and SMITH*, Circuit Judges.

JAMES C. HILL, Circuit Judge:

This appeal addresses two separate criminal actions joined at trial and consolidated for purposes of oral argument on appeal. For clarity and efficiency we address both actions in one opinion, setting out a separate disposition as to each appellant.

I. INTRODUCTION

Appellants herein, Philip Weinstein, Wilhelmina Harich Weinstein,1 Solomon Richman, Robert Falvo, and Stanley Kowitt (hereinafter and collectively, "appellants"), were convicted by jury trial in the United States District Court for the Southern District of Florida of conspiracy in violation of the Racketeer Influenced and Corrupt Organizations Act, 18 U.S.C. Secs. 1961-68 (1982) ("RICO"), and of one or more counts of mail or wire fraud in violation of 18 U.S.C. Secs. 1341-1343 (1982). Each appellant appeals his or her conviction, alleging insufficient evidence to support prosecution under RICO. A number of evidentiary, constitutional, and procedural grounds of error are also raised.2

The crime which the government sought to prove was a simple one, a conspiracy to defraud pharmaceutical manufacturers by misrepresentations made through use of interstate mail and wire transmissions. The case is complicated, however, by the context in which this crime took place, the so-called diversion market of the American pharmaceutical industry. An understanding of the case therefore requires an understanding of diversion and its role in the marketing of pharmaceuticals in this country.

II. FACTUAL BACKGROUND

A. Diversion In the American Pharmaceutical Industry

The Robinson Patman Act, 15 U.S.C. Sec. 13 et seq. (1982), prohibits anticompetitive discrimination in the pricing of goods sold for use, consumption or resale within the United States. An exception to the Act allows discriminatory prices for sales to nonprofit organizations. By its terms, the Act does not cover sales of goods for export.

In response to the Act, pharmaceutical manufacturers maintain a bifurcated pricing structure. One price is quoted for drugs sold to domestic wholesalers for resale in the United States. A much lower price is quoted for sales to exporters and nonprofit organizations. Pharmaceutical manufacturers thus discount products sold to exporters and nonprofit organizations. In most cases, the pharmaceutical products so sold are exported for resale in foreign countries or are used by nonprofit organizations for charitable purposes. Occasionally, however, exporters or nonprofit organizations may purchase a surplus of pharmaceutical products and later seek to resell that surplus in the domestic market. Because Robinson Patman only prohibits discriminatory pricing with anticompetitive effect, it is contended that it does not apply to such resales; no issue is raised as to that position. Notably, resale under these circumstances is also at a significant advantage. Nonprofit and export organizations can, because of the low price at which they were able to obtain the products, undercut the domestic prices pharmaceutical manufacturers offer on their own goods. This is the diversion market. It is a significant source of supply for many discount pharmacies and hospitals throughout the nation.

Understandably, diversion is unpopular with pharmaceutical manufacturers. While there was testimony in this case that in many instances pharmaceutical manufacturers used nonprofit and export organizations as a "dumping-ground" for pharmaceutical products nearing expiration, it was clear that many pharmaceutical houses actively seek to prevent diversion of products sold to export and nonprofit organizations. Some companies, in fact, go so far as to maintain investigators whose sole function is to trace sources of diversion supply.

These facts inform our disposition of the case. They are not, however, ultimately material to our decision. The financial motives a pharmaceutical manufacturer may have to favor or disfavor diversion are a matter of company policy. Diversion, whether boon or bane to the pharmaceutical industry, is not contended to be illegal as a matter of federal law.

B. The Conspiracy Scenario

While it represents no illegality in itself, the diversion industry clearly presents unique opportunities for the development of fraudulent practices. The appellants, most of whom were established diverters, were convicted of using the interstate mail and wires to misrepresent themselves to pharmaceutical manufacturers as nonprofit or export organizations in order to obtain pharmaceuticals. That mail and wire fraud is the crime with which this appeal is concerned. We turn to the proof put on by the government at trial.

In May, 1975, John Berkey, a commodities broker, was authorized to establish an American branch of Opus Christi, a legitimate, nondenominational, charitable organization headquartered in Rome, Italy and dedicated to the distribution of medicines and foodstuffs to developing countries. Berkey registered Opus Christi as a nonprofit corporation in the District of Columbia and opened offices in the Watergate complex. Uneducated in the pharmaceutical business, Berkey contacted David Pollard, another commodities broker, and indicated to Pollard that, through Opus Christi's status as a charitable organization, Berkey would be able to acquire pharmaceutical products at preferential prices. Berkey merely required expertise as to which pharmaceutical products to purchase and at what prices. Pollard, responding to Berkey's request, contacted Philip Weinstein, Peter Fixler, and Lionel Harris, parties whom Pollard felt would be interested in Berkey's proposition because of their acquaintance with the diversion industry. Weinstein, Fixler and Harris, in response to Pollard's information, formed American Medicinal International, Ltd. ("AMI") as an outlet for the sale in the diversion market of pharmaceutical products obtained by Berkey through Opus Christi.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Steele v. United States No. 1
267 U.S. 498 (Supreme Court, 1925)
Glasser v. United States
315 U.S. 60 (Supreme Court, 1942)
Kotteakos v. United States
328 U.S. 750 (Supreme Court, 1946)
Stirone v. United States
361 U.S. 212 (Supreme Court, 1960)
Chapman v. California
386 U.S. 18 (Supreme Court, 1967)
United States v. Marion
404 U.S. 307 (Supreme Court, 1971)
United States v. Lovasco
431 U.S. 783 (Supreme Court, 1977)
United States v. Turkette
452 U.S. 576 (Supreme Court, 1981)
Bell v. United States
462 U.S. 356 (Supreme Court, 1983)
United States v. Leon
468 U.S. 897 (Supreme Court, 1984)
Chow Bing Kew v. United States
248 F.2d 466 (Ninth Circuit, 1957)
United States v. Theodore Ray Melancon
462 F.2d 82 (Fifth Circuit, 1972)
United States v. Louis M. Darensbourg
520 F.2d 985 (Fifth Circuit, 1975)
United States v. Richard Callahan
551 F.2d 733 (Sixth Circuit, 1977)
United States v. Ralph Luther Blevins
555 F.2d 1236 (Fifth Circuit, 1977)
United States v. Elliott
571 F.2d 880 (Fifth Circuit, 1978)
United States v. Richard Callahan
579 F.2d 398 (Sixth Circuit, 1978)

Cite This Page — Counsel Stack

Bluebook (online)
762 F.2d 1522, 18 Fed. R. Serv. 757, 1985 U.S. App. LEXIS 30627, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-philip-weinstein-dr-philip-adamelli-wilhelmina-harich-ca11-1985.